Hereditary Angioedema News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Hereditary Angioedema Pipeline Global Briefing 2018 - Facts of Week



Hereditary Angioedema Pipeline Global Briefing 2018 
Facts of Week
Hereditary Angioedema- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding ...

and more » 


Shire Announces FDA Acceptance of sBLA for CINRYZEŽ for Pediatric Hereditary Angioedema Use - GlobeNewswire (press release)



MD Magazine
 
Shire Announces FDA Acceptance of sBLA for CINRYZEŽ for Pediatric Hereditary Angioedema Use 
GlobeNewswire (press release)
CAMBRIDGE, MA - February 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the U.S. Food and Drug Administration (FDA) accepted the CINRYZEŽ (C1 esterase inhibitor [human ...
FDA Grants Priority Review to C1 Esterase Inhibitor for HAE MD Magazine
Your Daily Pharma Scoop: Shire Looks Attractive, Omeros Data, Axovant Restructuring Seeking Alpha

all 3 news articles » 


FDA Accepts Shire's BLA and Grants Priority Review for Lanadelumab for the Prevention of Attacks in HAE Patients - GlobeNewswire (press release)



PharmaTimes
 
FDA Accepts Shire's BLA and Grants Priority Review for Lanadelumab for the Prevention of Attacks in HAE Patients 
GlobeNewswire (press release)
Cambridge, Mass. - February 23, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) today announced the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for lanadelumab (SHP643 ...
Priority review for Shire's HAE drug PharmaTimes

all 2 news articles » 


Global Hereditary Angioedema Market 2017-2025 - Expected to ... - Business Wire (press release)



Global Hereditary Angioedema Market 2017-2025 - Expected to ... 
Business Wire (press release)
The global hereditary angioedema market was valued at US$ 1,750.2 Million in 2016, and is expected to reach US$ 3,689.4 Million by 2025 expanding at a CAGR of 8.19% from 2017 to 2025. In 2016, C1 esterase inhibitors segment dominated the market due to ...

and more » 


Hereditary Angioedema: Hundreds of Australians could have ... - Daily Telegraph



Daily Telegraph
 
Hereditary Angioedema: Hundreds of Australians could have ... 
Daily Telegraph
HUNDREDS of Australians may be living with an undiagnosed medical condition that can make body parts swell frighteningly ? and even kill. Hereditary Angioedema (HAE) is a genetic condition with symptoms that include severe swelling of tissues ...

and more » 


FDA offers quick review for Shire's prospective blockbuster lanadelumab; Big Pharma loves big buybacks - Endpoints News



Endpoints News
 
FDA offers quick review for Shire's prospective blockbuster lanadelumab; Big Pharma loves big buybacks 
Endpoints News
The FDA is helping Shire $SHPG hustle along its application for lanadelumab, which the big biotech believes can peak out at $2 billion in revenue if it can get approved for hereditary angioedema. The agency accepted their application and provided a ...
B.Riley FBR Thinks Shire's Stock is Going to Recover Analyst Ratings

all 3 news articles » 


Shire to Present Data at 2018 AAAAI/WAO Joint Congress ... - GlobeNewswire (press release)



Shire to Present Data at 2018 AAAAI/WAO Joint Congress ... 
GlobeNewswire (press release)
CAMBRIDGE, Mass. - February 20, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that new immunology data will be presented at the 2018 American Academy of Allergy, Asthma & Immunology (AAAAI ...

and more » 


Hereditary Angioedema Market Overview, Industry Research ... - The Financial



Hereditary Angioedema Market Overview, Industry Research ... 
The Financial
Hereditary Angioedema Market Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 ? marketed, Phase III products, Drugs Profiles and route of synthesis. The Hereditary Angioedema Market report is an in-depth market study providing ...

and more » 


Shire Submits sBLA for HAE Therapy to Include Pediatric Indication - Rare Disease Report



Rare Disease Report
 
Shire Submits sBLA for HAE Therapy to Include Pediatric Indication 
Rare Disease Report
The FDA has accepted a supplemental Biologics License Application (sBLA) for Shire's Cinryze, a therapy that treats recurring swelling attacks in hereditary angioedema (HAE), to expand the already approved indication to include children 6 years and ...

 


Why significant BioCryst shareholder plans to vote against Idera merger - Triangle Business Journal



Triangle Business Journal
 
Why significant BioCryst shareholder plans to vote against Idera merger 
Triangle Business Journal
It believes BioCryst's lead product candidate, BCX7353, for the treatment of hereditary angioedema "has a present value of well over $1.5 billion, more than three times the current market capitalization of BCRX." In a filing with the SEC on Tuesday ...
Financial Newsletter - Zacks Zacks
Idera Pharmaceuticals, Inc. - IDRA - Stock Price Today - Zacks Zacks
SEC FORM 4 - SEC.gov SEC.gov

all 52 news articles »